The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

26 Jan 2016 07:00

RNS Number : 9438M
Ideagen PLC
26 January 2016
 

26 January 2016

 

Ideagen PLC

("Ideagen" or the "Group")

 

Unaudited Interim Results for the six months ended 31 October 2015

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces its unaudited interim results for the six months ended 31 October 2015.

 

Financial Highlights

· Revenue increased by 75% to £9.87m (2014: £5.65m)

o Underlying organic growth of 6%

o Recurring revenues represent 53% (2014: 53%) of overall revenues and cover 87% (2014: 86%) of fixed operating overheads

· Adjusted diluted EPS** increased by 16% to 0.98p (2014: 0.84p)

· Adjusted EBITDA* increased by 65% to £2.41m (2014: £1.46m)

· Adjusted PBT** increased by 65% to £2.13m (2014: £1.29m)

· Cash generated by operations of £1.15m (2014: £0.48m)

· Net cash of £5.44m (30 April 2015: £5.27m; 31 October 2014: £2.81m)

· 11% increase in interim dividend to 0.061p (2014: 0.055p)

 

*Before share based payments and exceptional items

**Before share based payments, amortisation of acquisition intangibles and exceptional items

 

Operational Highlights

· Significant progress within cloud business

o Release of new functionality within the Enlighten product, Ideagen's cloud based GRC solution

o 4 new Enlighten customer wins

o Industry recognition for Enlighten with GRC 20/20 Award for technical innovation

o Post period end granted a £4.9m Award Decision Notice for Enlighten

· Over 50 new on premise customer wins including Schiphol Airport, Kyocera and Fokker

· Strong customer retention - 97% maintenance and support contract renewal rate

· Significant contract extensions from existing customers including PWC, BBVA and Meggitt

 

David Hornsby, CEO of Ideagen, commented: "We are pleased with the strong first half performance, characterised by further profitable growth as a result of new customer wins and expanding our footprint within our existing base of over 2,200 customers. We have been delighted by the early customer interest and industry recognition for our recently launched cloud-based product, Enlighten, which we see as a significant opportunity for the Group.

 

"Trading remains robust across all GRC product areas and we have continued our sales momentum through the third quarter. Therefore, given the performance of the Group in the year to date, the growing contracted recurring revenue base, and healthy pipeline of new sales opportunities, the Board is confident in the outlook for the year as a whole."

 

Enquiries:

 

Ideagen plc

01629 699100

David Hornsby, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Stuart Andrews/James Thompson (Nomad)

 

Stephen Norcross (Corporate Broking)

 

 

 

Alma PR

020 8004 4218

Josh Royston

 

Hilary Buchanan

 

 

 

 

 

About Ideagen plc

 

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L). Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in eGRC (Enterprise Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

 

The Group has a customer base of over 2,200 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

 

For further information please visit www.ideagen.com

 

 

 

CHIEF EXECUTIVE'S REVIEW

 

Business Review

This has been another period of solid growth for the Group, with underlying organic growth of 6%. Organic growth has been augmented by the contribution of the integrated Gael and EIBS businesses, resulting in overall Group revenue growth of 75%, adjusted EBITDA growth of 65% and adjusted diluted EPS growth of 16%.

 

The Group's core expertise is in the development and implementation of Governance, Risk and Compliance (GRC) software tools that enable customers to identify, assess and prioritise risk and to manage information in line with rigorous regulations. In each of our chosen verticals, our customers are increasingly required to take a holistic view of risk management, internal audit and compliance, with many organisations at the beginning of the adoption phase of sophisticated, enterprise-wide solutions.

 

Demand in all of the Group's key GRC verticals continue to be robust, with new customer wins achieved across a range of industries. Growth in the period has been driven by a combination of new customer wins and expanding our footprint within the existing customer base of more than 2,200 organisations. New wins include Schiphol Airport, HNZ Global, Fokker, Providence Healthcare, Edmundson Electrical and Kyocera. Significant orders from the existing customer base include PWC, BBVA, Meggitt and BTG.

 

The Group continues to benefit from a strong base of recurring revenues, which now represent 53% of revenue (2014: 53%), covering 87% of the fixed overhead base (2014: 86%). Additionally 24% of revenue was derived from additional licence and service sales to existing customers. Therefore 77% of revenue is either recurring or repeatable in nature providing strong visibility over future earnings. In the period, 23% of revenue was derived from brand new customer wins.

 

During the period we have been pleased with the success of our recently launched SaaS-based Enlighten platform. Post period end the Group announced an Award Decision Notice from a Public Sector organisation stating its intent to procure Enlighten in a contract that is expected to be worth £4.9m over 5 years. As previously announced, the formal procurement process was subject to a mandatory standstill period. The standstill period has now ended and the contract is expected to be executed in the near future. As rapid delivery of the solution is essential to the customer, the Group, as an interim measure, has agreed to work under a short term contract to expedite immediate initiation whilst the 5 year contract is finalised. The programme is therefore well underway and the Group expects to generate significant revenues from the customer this financial year.

 

While the contribution of cloud based SaaS revenue to total Group revenue is currently modest, we are confident that Enlighten will be profitable and cash generative in the Group's 2016-2017 financial year. The Group has continued to invest in the required product development and sales resources and we view this as an area of significant potential growth for the business.

 

 

Markets: GRC and Content & Clinical

The Group operates in two areas: supplying GRC solutions to highly regulated industries including Healthcare, Complex Manufacturing, Finance and Transport; and, through leveraging our core technology, we operate a parallel business in the supply of Content and Clinical management solutions, predominately to the NHS. The Group has established a broad customer base across both markets, including 7 of the top 10 UK accounting firms; 125 of the 165 English NHS Acute Trusts; all 7 of the top 7 Global Aerospace & Defence companies; and 14 of the 14 Scottish Regional Health Boards.

 

GRC represents the greatest part of Ideagen revenues (c. 77%) and the Group believes will continue to be the core driver of overall growth. The market remains highly fragmented - there is no one dominant supplier but rather numerous smaller vendors providing niche product sets. We believe that, with our broad product portfolio and best of breed capabilities, the Group has realised only a small proportion of the available opportunity to date.

 

23% of Group revenue is derived from our Content and Clinical solutions. This area of the Group's operations continue to be impacted by delays in decision making within acute NHS trusts, typically around enterprise patient information opportunities. This is due to budgetary constraints at acute trust level as no additional technology fund has been made available for the current financial year to support the Government Paperless NHS strategy. However, outlook for the business remains encouraging over the medium term as it is likely that the central technology fund will be reintroduced in 2016-2017, following which there will be a locally funded Sustainability and Transformation Plan (STP) which will focus on digital initiatives at acute trust level.

 

Acquisitions

As previously announced, the integration of EIBS and Gael has provided a robust business platform. The Board continues to pursue acquisition opportunities in line with its stated strategy of acquiring complementary businesses that have strong IP and significant recurring revenues.

 

Product Strategy

 

''On Premise''

The focus for on premise product development going forward will be the closer integration of the established product set. The demand from customers continues to evolve toward the need for robust operational risk management across the enterprise combining the need for big data analysis with the escalation of information available within a corporate environment. We believe the optimum way to achieve this is through the implementation of a single, modular platform.

 

As such, our efforts will be on the closer integration of our best-in-breed product set to unify all product components (development standards, installation method, user interface) into a single standard format, and to enable product interoperability - or the exchange of data across each product - through a common service bus. This will allow us to rationalise the product set to avoid any duplicate functionality whilst providing a modular platform.

 

The ability to deliver this comprehensive capability through a modular portal will enable us to continue to pursue a 'land and expand' growth strategy as well as move into complementary industry verticals.

 

''Cloud''

To ensure that the Group is able to take advantage of the growing demand for cloud based solutions we have continued to invest in Enlighten, a risk-based, ultra-modern GRC software product. Enlighten has been designed for large enterprise and built for the cloud using Amazon Web Services (AWS). It contains all the rich features that any large, highly regulated organisation needs to achieve exceptional performance while managing compliance, quality and safety.

 

Enlighten is suitable for large enterprises who have a dispersed workforce, require rapid deployment and fast access to a GRC platform often through a mobile device. For example the large Public Sector customer referred to earlier intends to make Enlighten available to over 70,000 users to allow real time reporting of incidents to drive safety across an entire industry.

 

We were also delighted that during the period, Enlighten was recognised for its technical innovation by the 4th Annual GRC 20/20 Awards. The GRC 20/20 Awards recognise the leading GRC (Governance, Risk and Compliance) software products on the market. GRC 20/20 named Ideagen's Enlighten product as the most innovative product in its Environmental Health & Safety category. Judges were impressed with Enlighten's scalability, user experience, analytics and mobile capability.

 

Current Trading & Outlook

Trading remains robust across all GRC product areas and we have continued our sales momentum through the third quarter. Therefore, given the performance of the Group in the year to date, the growing contracted recurring revenue base, and healthy pipeline of new sales opportunities, the Board is confident in the outlook for the year as a whole.

 

 

David Hornsby

Chief Executive Officer

FINANCIAL REVIEW

 

Revenue for the 6 months ended 31 October 2015 increased by 75% to £9.87m (2014: £5.65 m). Organic growth in revenue was 6% based on a comparison of revenue in the period under review with pro-forma revenue for the comparative period adjusted for the Gael and EIBS acquisitions. Recurring revenues represent 53% (2014: 53%) of overall revenues and cover 87% (2014: 86%) of fixed operating overheads.

 

Adjusted EBITDA increased by 65% to £2.41m (2014: £1.46m). Amortisation of acquired intangibles of £1.86m (2014: £0.86m) represents the majority of the total depreciation and amortisation charge. The increase in the period is mainly attributable to the acquisition of Gael in January 2015.

 

The adjusted group tax charge was £0.31 million (2014: £0.20 million). This has been adjusted to exclude the deferred taxation associated with the amortisation of acquired intangibles and share based payment charges. The adjusted group tax charge represents 15% (2014: 16%) of adjusted PBT of £2.13m (2014: £1.29 million). The Group continues to benefit from the availability of R&D taxation credits.

 

As a result of the above, adjusted diluted earnings per share increased by 16% to 0.98p (2014: 0.84p).

 

The Group's financial position has continued to strengthen with net assets increasing to £31.8m (30 April 2015: £31.2m; 31 October 2014: £14.0m). The significant increase on 2014 was largely due to the £17.5 million share placing to support the acquisition of Gael. Net current assets increased to £2.69m (30 April 2015: £1.23m; 31 October 2014: £1.79m).

 

Cash generated by operations amounted to £1.15m (2014: £0.48m) representing 48% (2014: 33%) of adjusted EBITDA. Cash generated by operations is normally lower in the first half of the year partly due to the payment of a number of larger annual overheads in this period. Trade and other payables reduced by £1.16m in the six months to 31 October 2015. The Group ended the period with cash balances of £5.44m (30 April 2015: £ 5.27m; 31 October 2014: £2.81m) and no debt.

 

At 31 October 2015 deferred consideration of £3.2m was payable in respect of the acquisition of Gael of which £1.6m has subsequently been paid in January 2016 and £1.6m is payable in January 2017.

 

Dividend

The Board proposes increasing the interim dividend by 11% to 0.061 pence per share (2014: 0.055 pence per share) payable on 10 March 2016 to shareholders on the register on 19 February 2016. The corresponding ex-dividend date is 18 February 2016.

 

Graeme Spenceley

Finance Director

Ideagen plc

Consolidated Statement of Comprehensive Income for the six months ended 31 October 2015

 

 

 

Six months ended

31 October 2015

 

Six months ended

31 October 2014

 

£'000

£'000

Revenue

 

9,867

 

5,653

Cost of sales

 

(1,206)

 

(949)

Gross profit

 

8,661

 

4,704

Operating costs

 

(6,254)

 

(3,247)

Profit from operating activities before depreciation, amortisation,

share-based payment charges and exceptional items

 

2,407

 

1,457

 

 

 

 

 

Depreciation and amortisation

 

(2,141)

 

(847)

Share-based payment charges

 

(384)

 

(85)

Costs of acquiring businesses

 

-

 

(74)

(Loss) / profit from operating activities

 

(118)

 

451

 

 

 

 

 

Finance income

 

3

 

2

(Loss) / profit before taxation

 

(115)

 

453

Taxation credit / (charge)

 

121

 

(75)

Profit for the period

 

6

 

378

 

 

 

 

 

Other comprehensive income

 

 

 

 

Exchange differences on translating foreign operations

 

(10)

 

13

 

 

 

 

 

Total comprehensive income for the period attributable to the owners of the parent company

 

(4)

 

391

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

Pence

 

Pence

 

 

 

 

 

Basic

 

0.00

 

0.31

Diluted

 

0.00

 

0.29

 

 

Ideagen plc

Consolidated Statement of Financial Position at 31 October 2015

 

31 October 2015

 

30 April 2015

 

31 October 2014

 

£'000

 

£'000

 

£'000

Assets and liabilities

 

 

 

 

 

Non-current assets

 

 

 

 

 

Intangible assets

33,891

 

35,050

 

13,419

Property, plant and equipment

339

 

302

 

202

Deferred income tax assets

962

 

876

 

171

 

35,192

 

36,228

 

13,972

Current assets

 

 

 

 

 

Inventories

55

 

55

 

96

Trade and other receivables

7,312

 

7,332

 

4,024

Cash and cash equivalents

5,442

 

5,266

 

2,806

 

12,809

 

12,653

 

6,926

Current liabilities

 

 

 

 

 

Trade and other payables

2,206

 

3,476

 

1,623

Contingent consideration on business combinations

47

 

47

 

327

Current income tax liabilities

129

 

44

 

492

Deferred revenue

6,108

 

6,228

 

2,697

Deferred consideration on business combinations

1,628

 

1,628

 

-

 

10,118

 

11,423

 

5,139

Non-current liabilities

 

 

 

 

 

Deferred consideration on business combinations

1,613

 

1,613

 

-

Deferred income tax liabilities

4,434

 

4,656

 

1,611

 

6,047

 

6,269

 

1,611

 

 

 

 

 

 

Net assets

31,836

 

31,189

 

13,968

 

 

 

Ideagen plc

Consolidated Statement of Financial Position at 31 October 2015 (continued)

 

31 October 2015

 

30 April 2015

 

31 October 2014

 

£'000

 

£'000

 

£'000

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

Issued share capital

1,789

 

1,773

 

1,229

Share premium

23,568

 

23,443

 

6,983

Merger reserve

1,167

 

1,167

 

1,167

Share-based payments reserve

956

 

653

 

635

Retained earnings

4,373

 

4,160

 

3,944

Foreign currency translation reserve

(17)

 

(7)

 

10

 

 

 

 

 

 

Equity attributable to owners of the parent

31,836

 

31,189

 

13,968

 

 

Ideagen plc

Consolidated Statement of Cash Flows for the six months ended 31 October 2015

 

Six months ended 31 October 2015

 

Six months ended 31 October 2014

 

£'000

 

£'000

Cash flows from operating activities

 

 

 

Profit for the period

6

 

378

Depreciation of property, plant and equipment

98

 

60

Loss on disposal of property, plant and equipment

2

 

-

Amortisation of intangible non-current assets

2,043

 

787

Business acquisition costs in profit or loss

-

 

74

Share-based payment charge

384

 

85

Finance income recognised in profit or loss

(3)

 

(2)

Taxation (credit) / charge recognised in profit or loss

(121)

 

75

Decrease in inventories

-

 

293

Decrease / (Increase) in trade and other receivables

19

 

(36)

Decrease in trade and other payables

(1,158)

 

(1,060)

Decrease in deferred revenue

(119)

 

(173)

Cash generated by operations

1,151

 

481

Interest received

3

 

2

Income tax repaid

8

 

64

Business acquisition costs paid

(102)

 

(146)

Net cash generated by operating activities

1,060

 

401

 

 

 

 

Cash flows from investing activities

 

 

 

Payments of deferred consideration on business combinations

-

 

(50)

Net cash outflow on acquisition of businesses net of cash acquired

-

 

(1,259)

Payments for development costs

(884)

 

(368)

Payments for property, plant and equipment

(150)

 

(65)

Proceeds of disposal of property, plant and equipment

12

 

-

Net cash used by investing activities

(1,022)

 

(1,742)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issue of shares under share option scheme

141

 

123

Net cash generated by financing activities

141

 

123

 

 

 

 

Net increase / (decrease) in cash and cash equivalents during the period

179

 

(1,218)

Cash and cash equivalents at the beginning of the period

5,266

 

4,011

Effect of exchange rate changes on cash balances held in foreign currencies

(3)

 

13

Cash and cash equivalents at the end of the period

5,442

 

2,806

 

Ideagen plc: Consolidated Statements of Changes in Equity

 

 

Share

capital

 

Share

premium

 

Merger

Reserve

 

Share-based payments reserve

 

Retained earnings

 

Foreign

currency translation reserve

 

Total

attributable to owners of the parent

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

£'000

 

£'000

 

£'000

 

£'000

 

£'000

 

£'000

 

£'000

For the six months to 31 October 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 1 May 2015

1,773

 

23,443

 

1,167

 

653

 

4,160

 

(7)

 

31,189

Profit for the period

-

 

-

 

-

 

-

 

6

 

-

 

6

Share-based payments

-

 

-

 

-

 

384

 

-

 

-

 

384

Shares issued under share option scheme

16

 

125

 

-

 

-

 

-

 

-

 

141

Transfer on exercise of share options

-

 

-

 

-

 

(81)

 

81

 

-

 

-

Taxation on share-based payments in equity

-

 

-

 

-

 

-

 

126

 

-

 

126

Other comprehensive income for the period

-

 

-

 

-

 

-

 

-

 

(10)

 

(10)

At 31 October 2015

1,789

 

23,568

 

1,167

 

956

 

4,373

 

(17)

 

31,836

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the six months to 31 October 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At 1 May 2014

1,219

 

6,870

 

1,167

 

596

 

3,520

 

(3)

 

13,369

Profit for the period

-

 

-

 

-

 

-

 

378

 

-

 

378

Share-based payments

-

 

-

 

-

 

85

 

-

 

-

 

85

Shares issued under share option scheme

10

 

113

 

-

 

-

 

-

 

-

 

123

Transfer on exercise of share options

-

 

-

 

-

 

(46)

 

46

 

-

 

-

Other comprehensive income for the period

-

 

-

 

-

 

-

 

-

 

13

 

13

At 31 October 2014

1,229

 

6,983

 

1,167

 

635

 

3,944

 

10

 

13,968

 

Ideagen plc: Consolidated Statement of Changes in Equity for the year ended 30 April 2015

 

 

Share

capital

 

Share

premium

 

Merger

reserve

 

Share-based payments reserve

 

Retained earnings

 

Foreign

currency translation reserve

 

Total

attributable to owners of the parent

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

£'000

 

 £'000

 

£'000

 

£'000

 

£'000

 

£'000

 

£'000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 May 2014

1,219

 

6,870

 

1,167

 

596

 

3,520

 

(3)

 

13,369

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share placing

515

 

16,985

 

-

 

-

 

-

 

-

 

17,500

Share placing issue costs

-

 

(584)

 

-

 

-

 

-

 

-

 

(584)

Shares issued under share option scheme

39

 

172

 

-

 

-

 

-

 

-

 

211

Profit for the year

-

 

-

 

-

 

-

 

480

 

-

 

480

Other comprehensive income for the year

-

 

-

 

-

 

-

 

-

 

(4)

 

(4)

Share-based payments

-

 

-

 

-

 

142

 

-

 

-

 

142

Transfer on exercise of share options

-

 

-

 

-

 

(85)

 

85

 

-

 

-

Taxation on share-based payments in equity

-

 

-

 

-

 

-

 

294

 

-

 

294

Equity dividends paid

-

 

-

 

-

 

-

 

(219)

 

-

 

(219)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 30 April 2015

1,773

 

23,443

 

1,167

 

653

 

4,160

 

(7)

 

31,189

 

Ideagen plc

Notes to the interim financial information

1 Basis of information

The interim financial information for the 6 months ended 31 October 2015 and the six months ended 31 October 2014 included in this announcement is unaudited. The financial information for the year ended 30 April 2015 included in this announcement does not constitute the annual report and accounts of the Company for the year ended 30 April 2015 within the meaning of section 434 of the Companies Act 2006. The audited annual report and financial statements of the Company for the year ended 30 April 2015 has been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain any statement under section 498 (2) or (3) of the Companies Act 2006 and did not include references to any matters to which the auditor drew attention by way of emphasis. Consistent accounting policies have been applied in the preparation of this information unless otherwise stated below.

 

2 Earnings per share information

Basic earnings per share is calculated by dividing the profit for the period attributable to the owners of the Company ('Earnings') by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is calculated by dividing Earnings by the weighted-average number of ordinary shares outstanding during the period as adjusted for the effect of all potentially dilutive shares, including share options.

In order to better demonstrate the performance of the Company, adjusted earnings per share calculations have also been presented which take into account items typically adjusted for by users of financial statements. The adjusted earnings and earnings per share information are shown below.

 

 

Earnings per share information

Six months ended 31 October 2015

 

Six months ended 31 October 2014

 

£'000

 

£'000

 

 

 

 

Profit for the period (Earnings)

6

 

378

 

 

 

 

Adjustments:

 

 

 

Share-based payment charges

384

 

85

Deferred taxation on share-based payment charges

(64)

 

2

Costs of acquiring businesses

-

 

74

Amortisation of acquired intangibles

1,859

 

679

Deferred taxation on amortisation of acquired intangibles

(370)

 

(131)

Adjusted earnings

1,815

 

1,087

 

 

 

 

Weighted average number of shares

177,871,466

 

122,625,927

Diluted weighted average number of shares

186,023,737

 

129,543,520

 

 

 

 

Basic earnings per share

0.00 pence

 

0.31 pence

Diluted earnings per share

0.00 pence

 

0.29 pence

Basic adjusted earnings per share

1.02 pence

 

0.89 pence

Diluted adjusted earnings per share

0.98 pence

 

0.84 pence

3 Taxation

Further information on the taxation charge in the Statement of Comprehensive Income is as follows:

 

Six months ended 31 October 2015

£'000

 

Six months ended 31 October 2014

£'000

 

 

 

 

Income taxation charge

60

 

144

 

 

 

 

Deferred tax credit on amortisation of acquisition intangibles

(370)

 

(131)

Deferred tax on share based payment charges

(64)

 

2

Deferred tax charge on utilisation of tax losses

104

 

-

Deferred tax charge on development costs

149

 

60

Total deferred income taxation credit

(181)

 

(69)

 

 

 

 

Total taxation (credit) / charge

(121)

 

75

 

4 Adjusted profit before taxation and adjusted taxation charge

 

6 months ended 31 October 2015

£'000

 

6 months ended 31 October 2014

£'000

 

 

 

 

Adjusted earnings (note 2)

1,815

 

1,087

Adjusted taxation charge (below)

313

 

204

Adjusted profit before taxation

2,128

 

1,291

 

 

 

 

Taxation in the Statement of Comprehensive Income

(121)

 

75

Add back:

 

 

 

Deferred taxation credit on amortisation of acquisition intangibles (note 3)

370

 

131

Deferred taxation on share based payment charges

64

 

(2)

Adjusted taxation charge

313

 

204

 

 

 

 

Adjusted taxation charge based on adjusted profit before taxation

14.7%

 

15.8%

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR BCGDBBDDBGLU
Date   Source Headline
8th Jul 20227:00 amRNSCancellation - Ideagen Plc
8th Jul 20227:00 amBUSForm 8.3 - Ideagen PLC
7th Jul 20223:45 pmRNSHolding(s) in Company
7th Jul 20223:30 pmGNWForm 8.3 - Ideagen plc
7th Jul 20223:20 pmRNSForm 8.3 - Ideagen plc
7th Jul 20223:00 pmRNSForm 8.3 - Ideagen PLC
7th Jul 20221:30 pmBUSForm 8.3 - IDEAGEN PLC
7th Jul 20221:19 pmGNWForm 8.3 - Ideagen PLC
7th Jul 202211:21 amRNSForm 8.3 - Ideagen plc
7th Jul 202210:39 amRNSForm 8.5 (EPT/RI)
7th Jul 20229:08 amRNSForm 8.5 (EPT/RI) - Ideagen Plc
7th Jul 20227:30 amRNSSuspension – Ideagen PLC
7th Jul 20227:00 amRNSHolding(s) in Company
7th Jul 20227:00 amRNSScheme becomes Effective
6th Jul 20223:30 pmGNWForm 8.3 - Ideagen plc
6th Jul 20223:20 pmRNSForm 8.3 - Ideagen plc
6th Jul 20223:10 pmRNSHolding(s) in Company
6th Jul 20223:00 pmRNSForm 8.3 - Ideagen PLC
6th Jul 20221:30 pmBUSForm 8.3 - IDEAGEN PLC
6th Jul 202211:41 amRNSForm 8.5 (EPT/RI)
6th Jul 202211:08 amGNWForm 8.3 - [IDEAGEN PLC - 05 07 2022] - (CGWL)
6th Jul 202211:03 amRNSForm 8.3 - IDEAGEN PLC
6th Jul 20229:09 amRNSForm 8.5 (EPT/RI) - Ideagen Plc
6th Jul 20229:00 amRNSForm 8 (DD) - Ideagen plc
6th Jul 20229:00 amRNSForm 8 (DD) - Ideagen plc
6th Jul 20227:00 amBUSForm 8.3 - Ideagen PLC
5th Jul 20223:30 pmGNWForm 8.3 - Ideagen plc
5th Jul 20223:00 pmRNSForm 8.3 - Ideagen PLC
5th Jul 20222:30 pmRNSExercise of Options, Issue of Equity and Rule 2.9
5th Jul 20222:20 pmRNSCourt Sanction of Scheme of Arrangement
5th Jul 202212:24 pmGNWForm 8.3 - [IDEAGEN PLC 04 07 2022] - (CGWL)
5th Jul 202212:13 pmRNSDisclosure under Rule 26
5th Jul 202212:10 pmRNSForm 8.3 - Ideagen plc
5th Jul 202210:58 amRNSForm 8.5 (EPT/RI)
5th Jul 20228:13 amRNSForm 8.5 (EPT/RI)
4th Jul 20223:30 pmGNWForm 8.3 - Ideagen plc
4th Jul 20223:20 pmRNSForm 8.3 - Ideagen plc
4th Jul 20223:00 pmRNSForm 8.3 - Ideagen PLC
4th Jul 20222:30 pmRNSHolding(s) in Company
4th Jul 202212:07 pmRNSForm 8.3 - Ideagen plc
4th Jul 202210:55 amRNSForm 8.5 (EPT/RI)
4th Jul 202210:47 amGNWForm 8.3 - [IDEAGEN PLC - 01 07 2022] - (CGWL)
4th Jul 20227:00 amBUSForm 8.3 - Ideagen PLC
1st Jul 20223:30 pmGNWForm 8.3 - Ideagen plc
1st Jul 20223:20 pmRNSForm 8.3 - Ideagen plc
1st Jul 20223:11 pmGNWForm 8.3 - [Ideagen plc - 30 06 2022] - (CGWL)
1st Jul 20223:09 pmRNSForm 8.3 - Ideagen plc
1st Jul 20223:00 pmRNSForm 8.3 - Ideagen PLC
1st Jul 20221:30 pmBUSForm 8.3 - IDEAGEN PLC
1st Jul 202212:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.